Hoffmann - La Roche - Database of Clinical Trials by Pharmaceutical Companies

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Hoffmann - La Roche

Top of Directory » All Categories » by Company » Hoffmann - La Roche



  • A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: RO5095932;   Drug: Placebo;   Drug: RO5095932;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • A Study With RO4917523 in Patients With Fragile X Syndrome

    Condition:   Fragile X Syndrome
    Interventions:   Drug: RO4917523;   Drug: Placebo;   Drug: RO4917523;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting - verified November 2009
  • A Study of CellCept (Mycophenolate Mofetil) in Lung Transplant Recipients

    Condition:   Lung Transplantation
    Intervention:   Drug: mycophenolate mofetil [CellCept]
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting - verified November 2009
  • An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys

    Condition:   Hepatitis B, Chronic
    Intervention:  
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer

    Conditions:   Stomach Cancer;   Gall Bladder Cancer;   Bile Ductus Cancer;   Pancreas Cancer;   Colorectal Cancer
    Intervention:   Other: oxaliplatin, capecitabine, radiotherapy
    Sponsors:   Lund University Hospital;   Roche Pharma AG;   Sanofi-Synthelabo
    Completed - verified November 2009
  • A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Intervention:   Drug: tocilizumab
    Sponsor:   Hoffmann-La Roche
    Active, not recruiting - verified November 2009
  • Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: Azacitidine;   Drug: Epoetin beta
    Sponsors:   Groupe Francophone des Myelodysplasies;   Celgene Corporation;   Roche Pharma AG
    Recruiting - verified November 2009
  • Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

    Condition:   Advanced Gastric Cancer
    Interventions:   Drug: Paclitaxel;   Drug: capecitabine;   Drug: capecitabine;   Drug: cisplatin
    Sponsors:   Peking University;   Roche Pharma AG
    Recruiting - verified November 2009
  • A Study of RO5072759 With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

    Condition:   Lymphocytic Leukemia, Chronic
    Interventions:   Drug: RO5072759;   Drug: rituximab;   Drug: chlorambucil
    Sponsors:   Hoffmann-La Roche;   Genentech
    Not yet recruiting - verified November 2009
  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009
  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease

    Condition:   COPD
    Intervention:   Drug: R7103
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

    Condition:   Malignant Melanoma
    Interventions:   Drug: RO5185426;   Drug: dacarbazine
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting - verified November 2009
  • Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU

    Condition:   Influenza A Virus H1N1 Subtype
    Intervention:   Drug: Oseltamivir
    Sponsors:   University of Manitoba;   Hoffmann-La Roche
    Not yet recruiting - verified November 2009
  • A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: rituximab [MabThera/Rituxan];   Drug: methotrexate;   Drug: methylprednisolone
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

    Condition:   Malignant Melanoma
    Interventions:   Drug: RO5185426;   Drug: Drug cocktail
    Sponsor:   Hoffmann-La Roche
    Not yet recruiting - verified October 2009
  • Computerized Glucose Control in Critically Ill Patients

    Conditions:   Hyperglycemia;   Critical Illness
    Interventions:   Device: CGAO-based Glucose Control;   Device: Standard-Care Glucose Control
    Sponsors:   Centre Hospitalier of Chartres;   Société Française d'Anesthésie et de Réanimation (SFAR);   Baxter Healthcare Corporation
    Recruiting - verified November 2009
  • Oseltamivir Pharmacokinetics in Morbid Obesity

    Condition:   Morbid Obesity
    Interventions:   Other: Patients with a BMI < 30 given Oseltamivir;   Other: Patients with a BMI > 40 given Oseltamivir
    Sponsors:   IWK Health Centre;   Canadian Center for Vaccinology;   Capital District Health Authority;   Dalhousie University;   Hoffmann-La Roche
    Not yet recruiting - verified October 2009
  • Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: infliximab, etanercept, adalimumab;   Drug: abatacept, rituximab or tocilizumab
    Sponsor:   University Hospital, Strasbourg, France
    Not yet recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials